Article

Generic Deferasirox Tablets Granted FDA Approval

Deferasirox is indicated for treating chronic iron overload caused by repeated blood transfusions in patients age 2 years and older.

Officials with the FDA have granted final approval to Glenmark Pharmaceuticals’ Deferasirox Tablets for Oral Suspension, 125 mg, 250 mg and 500 mg. The drug is the generic version of Exjade® (deferasirox, Novartis) Tablets for Oral Suspension, 125 mg, 250 mg and 500 mg.1

Deferasirox is indicated for treating chronic iron overload caused by repeated blood transfusions in patients age 2 years and older.2

Common adverse effects reported by patients in clinical trials taking deferasirox include nausea, vomiting, diarrhea, stomach pain, increases in kidney laboratory values, and skin rash. A boxed warning on Novartis’ deferasirox label indicates the drug may cause serious kidney problems, liver problems, and bleeding in the stomach or intestines.2

According to IQVIA sales data for the 12-month period ending November 2019, Norvartis’ deferasirox tablets for Oral Suspension, 125 mg, 250 mg and 500 mg garnered annual sales of approximately $106.4 million.1

REFERENCES

  • Glenmark Pharmaceuticals receives ANDA approval for Deferasirox Tablets for Oral Suspension, 125 mg, 250 mg and 500 mg [news release]. Mumbai, India; January 7, 2020: Glenmark website. https://www.glenmarkpharma.com/sites/default/files/Glenmark-receives-ANDA-approval-for-Deferasirox-Tablets-for-Oral-Suspens.pdf. Accessed January 7, 2020.
  • Novartis. Exjade® (deferasirox) tablets for oral suspension. Novartis website. https://www.us.exjade.com/. Published November 2019. Accessed January 7, 2020.

Related Videos
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
Pharmacy, Advocacy, Opioid Awareness Month | Image Credit: pikselstock - stock.adobe.com
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Hurricane Helene, Baxter plant, IV fluids shortage, health systems impact, injectable medicines, compounding solutions, patient care errors, clinical resources, operational consideration, fluid conservation, sterile water, temperature excursions, training considerations, patient safety, feedback request
Image Credit: © peopleimages.com - stock.adobe.com
Pharmacists, Education, Advocacy, Opioid Awareness Month | Image Credit: Jacob Lund - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards